Prosecution Insights
Last updated: April 19, 2026
Application No. 18/563,314

DINUCLEAR PLATINUM EMITTER COMPLEXES AND METHODS OF MAKING AND USING THEREOF

Non-Final OA §102§112
Filed
Nov 21, 2023
Examiner
DULKA, JOHN P
Art Unit
2817
Tech Center
2800 — Semiconductors & Electrical Systems
Assignee
Hong Kong Quantum AI Lab Limited
OA Round
1 (Non-Final)
83%
Grant Probability
Favorable
1-2
OA Rounds
2y 8m
To Grant
96%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allow Rate
688 granted / 825 resolved
+15.4% vs TC avg
Moderate +12% lift
Without
With
+12.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
28 currently pending
Career history
853
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
37.3%
-2.7% vs TC avg
§102
32.2%
-7.8% vs TC avg
§112
21.7%
-18.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 825 resolved cases

Office Action

§102 §112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Acknowledgement of preliminary amendment dated 11/21/2023 including remarks and amended abstract, specification and claims1. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Domestic Benefit Present application 18/563,314 filed 11/21/2023 is a National Stage entry of PCT/CN2022/096225 with international filing date of 05/31/2022. PCT/CN2022/096225 claims priority from provisional application 63/195,140 filed 05/31/2021. Foreign Priority No claim to an application for foreign priority. Four Information Disclosure Statements The four information disclosure statements respectively submitted on 05/17/24, 03/20/25, 04/15/25 and 07/23/25 were filed before first Office action. The submissions are in compliance with the provisions of 37 CFR 1.97. Accordingly, the four information disclosure statements have been considered. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-5, 7-8, 11-17, 19 and 29 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Independent claims 1 and 12 recite the term, “isomer”, however a person of ordinary skill in the art would not understand what/which compound is actually meant with the said term. The dependent claims do not remedy this indefiniteness and are rejected for incorporating the indefiniteness from their respective independent claims. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 7, 11, 20, 23 and 29 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by journal article entitled Photophysical Properties of Phosphorescent Mono- and Bimetallic Platinum(II) Complexes with C∧C* Cyclometalating NHC Ligands to Pinter et al. (“Pinter”). PNG media_image1.png 446 936 media_image1.png Greyscale Regarding independent claim 1 and dependent claims 7, 11 and 29, Pinter teaches of platinum complexes 2 and 3 with chemical structural diagrams in Scheme 1 on page 557. Complex 3 of Pinter appears to teach claim 7. Complex 2 of Pinter teaches claim 11. Pinter teaches claim 29 because there is an OLED mentioned with the aforementioned light emitters in column 1 of page 557. Regarding independent claim 20 and dependent claim 23, Pinter teaches of the preparation of complexes 2 and 3: 1-methyl-3-phenyl-3H-imidazo[4,5-b]pyridine-1-ium iodide reacts with Pt(COD)Cl2 and pyrazole (or 1Bu-pyrazole). See the experimental section in the right column on page 560 to paragraph 1 in the left column on page 561. Therefore, claim 20 and claim 23 are taught by Pinter. Allowable Subject Matter Claims 2-5 and 8 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. The combination needed to teach claims 2-5 and 8 appears to be impermissible hindsight. Claim 12 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. Regarding independent claim 12, the difference between claim 12 and the prior art of Pinter is that the pyrazole ligand bridging two metal platinums contain a linking group L. However, the two pyrazole ligands in Pinter are independent of each other, they are not connected to each other. As such, claim 12 and dependent claims thereof are allowed. Claims 13-17 and 19 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. Claims 25 and 27 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion The prior art made of record and not relied upon is considered pertinent to Applicant's disclosure as listed on the current Notice of References Cited-892 Form: Reference A: see column 3. Reference B: see Figures 2-4 Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN P DULKA whose telephone number is (571)270-7398. The examiner can normally be reached Monday-Friday, 9am-5pm, EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, ELISEO RAMOS-FELICIANO can be reached at (571)272-7925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. 07 January 2026 /John P. Dulka/Primary Examiner, Art Unit 2817 1 Claims 6,9,10,18,21,22,24,26,28 and 30-36 are canceled in preliminary amendment.
Read full office action

Prosecution Timeline

Nov 21, 2023
Application Filed
Jan 07, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12604511
SEMICONDUCTOR DEVICE
2y 5m to grant Granted Apr 14, 2026
Patent 12598738
SEMICONDUCTOR MEMORY DEVICE INCLUDING LOWER CONTACT PLUG PROTRUDING FROM SIDEWALL SPACERS
2y 5m to grant Granted Apr 07, 2026
Patent 12593709
SUBSTRATE(S) FOR AN INTEGRATED CIRCUIT (IC) PACKAGE EMPLOYING A CORE LAYER AND AN ADJACENT INSULATION LAYER(S) WITH AN EMBEDDED METAL STRUCTURE(S) POSITIONED FROM THE CORE LAYER
2y 5m to grant Granted Mar 31, 2026
Patent 12588183
SEMICONDUCTOR MEMORY STRUCTURE WITH BUTTED CONTACT AND METHOD FOR MANUFACTURING SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12581885
PROCESSING METHOD OF WAFER
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
83%
Grant Probability
96%
With Interview (+12.4%)
2y 8m
Median Time to Grant
Low
PTA Risk
Based on 825 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month